By Denny Jacob
Genelux named Matthew Pulisic as chief financial officer.
The late clinical-stage immuno-oncology granted the new executive a base salary of $410,000 and made him eligible for an annual discretionary bonus with a target amount of up to 40% of his then-current base salary based on certain achievements. Pulisic has also been granted an option to purchase 275,000 shares of common stock of the company with a per-share exercise price of $3.95 a share.
Pulisic most recently served as vice president of finance at Arrowhead Pharmaceuticals, an RNAi technology company.
Genelux's change at CFO comes as Lourie Zak resigned days earlier. She and the company entered into a separation agreement in which she will serve as a non-employee advisor that will conclude on Aug. 29 unless earlier terminated, among other terms.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 03, 2025 06:58 ET (11:58 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.